ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Bliss GVS Pharma Ltd reported the voting results of its postal ballot. Members approved the appointment of Mr. Santosh Parab as a Non-Executive and Non-Independent Director.
Bliss GVS Pharma allotted equity shares under its Employee Stock Option Scheme (ESOP). This increases the company's total paid-up share capital.
Bliss GVS Pharma allotted 55,250 equity shares under its Employee Stock Option Plan 2019 at an exercise price of Rs. 43 per share.
Anupam Rasayan India Ltd completed an open offer to acquire 26% of Bliss GVS Pharma Ltd. Only 1,669 shares were acquired for ₹4.99 Lakh.
Bliss GVS Pharma Ltd issued a Postal Ballot Notice to seek shareholder approval for the appointment of Mr. Santosh Parab as a Director.
Bliss GVS Pharma Ltd reported revenue from operations of ₹285.6 Cr (+37.6% YoY) and net profit of ₹51.4 Cr (+15.8% YoY) for Q1 FY27.
Bliss GVS Pharma Ltd has allotted 31,250 equity shares to eligible employees under its ESOP 2019 scheme. This action increases the company's total paid-up share capital.
Life Insurance Corporation of India reduced its stake in Bliss GVS Pharma Ltd by 2.15% via market sale. The institutional investor's holding decreased to 2.96%.
Bliss GVS Pharma Ltd will hold a board meeting on August 12, 2026. The board will consider and approve financial results for the quarter ended June 30, 2026.
Bliss GVS Pharma Ltd announced the resignation of Mr. Sachin Saboo, General Manager – Regulatory & Clinical, effective from the close of business hours on July 24, 2026.
Bliss GVS Pharma is transferring unclaimed dividends from 2018-2019 and related shares to the IEPF. Shareholders are notified to claim these funds by October 27, 2026.
Clarus Trust acquired an additional 0.18% stake in Bliss GVS Pharma via open market purchases, taking their total holding to 5.13%.
Anupam Rasayan India Ltd has launched an open offer to acquire up to 2.77 crore shares of Bliss GVS Pharma at ₹299 per share.
Bliss GVS Pharma Ltd received an addendum to the open offer's public announcement, adding Mates Visa Consultancy Pvt Ltd as a Person Acting in Concert.
Bliss GVS Pharma concluded its 41st AGM on July 15, 2026. Shareholders approved a 100% final dividend of Re. 1.00 per share for FY 2025-26.
Bliss GVS Pharma updated contact details for KMPs authorized to determine and report material events. This administrative update ensures compliance with SEBI LODR Regulation 30(5).